UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Leukemia, 2012-09, Vol.26 (9), p.2096-2102

2012

Volltextzugriff (PDF)

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

Leukemia, 2010-10, Vol.24 (10), p.1719-1724

2010

Volltextzugriff (PDF)

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

British journal of cancer, 2013-09, Vol.109 (6), p.1593-1598

2013

Volltextzugriff (PDF)

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL

Leukemia, 2006-04, Vol.20 (4), p.664-670

2006

Volltextzugriff (PDF)

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Leukemia, 2013-01, Vol.27 (1), p.107-112

2013

Volltextzugriff (PDF)

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

Leukemia, 2009-09, Vol.23 (9), p.1628-1633

2009

Volltextzugriff (PDF)

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

Leukemia, 2016-07, Vol.30 (7), p.1593-1596

2016

Volltextzugriff (PDF)

A novel BCR–ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia‐positive chronic myeloid leukaemia

British journal of haematology, 2000-06, Vol.109 (3), p.635-637

2000

Volltextzugriff (PDF)

GENOTYPIC DIVERSITY AND GENE FLOW IN BROODING AND SPAWNING CORALS ALONG THE GREAT BARRIER REEF, AUSTRALIA

Evolution, 2000-10, Vol.54 (5), p.1590-1605

2000

Volltextzugriff (PDF)

Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR

Leukemia, 2003-05, Vol.17 (5), p.821-828

2003

Volltextzugriff (PDF)

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance

Leukemia, 2013-04, Vol.27 (4), p.907-913

2013

Volltextzugriff (PDF)

Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years

Annals of internal medicine, 1993-08, Vol.119 (3), p.207

1993

Volltextzugriff (PDF)

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

The New England journal of medicine, 2019-12, Vol.381 (24), p.2315-2326

2019

Volltextzugriff (PDF)

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

The New England journal of medicine, 2014-09, Vol.371 (11), p.1005-1015

2014

Volltextzugriff (PDF)

Mobilization of predominantly Philadelphia chromosome‐negative blood progenitors using cyclophosphamide and rHUG‐CSF in early chronic‐phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control

British journal of haematology, 1997-03, Vol.96 (3), p.635-640

1997

Volltextzugriff (PDF)

Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia

Leukemia, 1997-04, Vol.11 (4), p.581-587

1997

Volltextzugriff (PDF)

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

Haematologica (Roma), 2012-05, Vol.97 (5), p.731-738

2012

Volltextzugriff (PDF)

Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD

Cytotherapy (Oxford, England), 2003-12, Vol.5 (6), p.534-541

2003

Volltextzugriff (PDF)

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

Haematologica (Roma), 2013-02, Vol.98 (2), p.193-200

2013

Volltextzugriff (PDF)

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T‐depleted donor marrow: feasibility of using busulphan alone for re‐conditioning

British journal of haematology, 1992-01, Vol.80 (1), p.33-39

1992

Volltextzugriff (PDF)

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH

Pathology, 1997-08, Vol.29 (3), p.289-293

1997

Volltextzugriff (PDF)

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

Haematologica (Roma), 2012-06, Vol.97 (6), p.907-914

2012

Volltextzugriff (PDF)

HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome

British journal of haematology, 1992-07, Vol.81 (3), p.383-390

1992

Volltextzugriff (PDF)

Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination

Proceedings of the National Academy of Sciences - PNAS, 1994-12, Vol.91 (25), p.11869-11873

1994

Volltextzugriff (PDF)

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Blood, 2002-05, Vol.99 (9), p.3472-3475

2002

Volltextzugriff (PDF)

1 – 25 von 4.169

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.904)
Mit Volltextzugriff
(3.306)

Publikationsform

Sprache

Englisch
(4.163)
Französisch
(5)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

A novel BCR–ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia‐positive chronic myeloid leukaemia

GENOTYPIC DIVERSITY AND GENE FLOW IN BROODING AND SPAWNING CORALS ALONG THE GREAT BARRIER REEF, AUSTRALIA

Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance

Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

Mobilization of predominantly Philadelphia chromosome‐negative blood progenitors using cyclophosphamide and rHUG‐CSF in early chronic‐phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control

Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T‐depleted donor marrow: feasibility of using busulphan alone for re‐conditioning

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome

Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Aktive Filter

Suchergebnisse filtern